[{"from": "human", "value": "Please give me some details about this molecule. [C][C][Branch1][C][C][Branch1][C][C][C][=N][C][=Branch2][Ring1][C][=C][Branch1][Ring2][S][Ring1][Branch1][C][=N][C][=Branch1][=Branch1][=N][C][=C][Ring1][=Branch1][N][C][=C][Branch2][Ring1][=N][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][Branch1][Branch2][C][=C][C][=C][Ring1][=Branch1][F][F][F]"}, {"from": "gpt", "value": "The molecule is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation.  In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) in combination have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene."}]